Camrelizumab combined with famitinib elicited responses and was well tolerated in patients with advanced melanoma previously exposed to an immune checkpoint inhibitor regimen.
Clinical Trials
Dr Coupe on the Investigation of IMM60 Plus Pembrolizumab in Advanced Melanoma and NSCLC
Nicholas Coupe, MBBS, PhD, oncologist, Oxford University Hospitals, NHS Foundation Trust, discusses the investigation of IMM60 plus pembrolizumab (Keytruda) in patients with advanced melanoma or metastatic non-small cell lung cancer (NSCLC).
Dr Monga on the Investigation of PRT811 in High-Grade Glioma or Uveal Melanoma
Varun Monga, MD, clinical associate professor, Internal Medicine, Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, discusses the investigation of the protein arginine methyltransferase 5 (PRMT5) brain-penetrant inhibitor PRT811 in patients with recurrent high-grade glioma or uveal melanoma.
Anti–LAG-3/PD-1 Combination Under Investigation as Adjuvant Therapy in High-Risk Melanoma
The combination of fianlimab and cemiplimab-rwlc (Libtayo) represents a wave of novel anti–LAG-3/PD-1 treatments being explored in patients with melanoma at high risk for relapse, according to the rationale and design of an ongoing phase 3 trial (NCT05608291) that were presented at the 2023 ASCO Annual Meeting.